Iclaprim

Iclaprim
Clinical data
Routes of
administration		intravenous
ATC code
Legal status
Legal status
  • Investigational
Identifiers
  • (RS)-5-[(2-Cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl)methyl]pyrimidine-2,4-diamine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.130.860 Edit this at Wikidata
Chemical and physical data
FormulaC19H22N4O3
Molar mass354.410 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • COC1=C(C2=C(C=CC(O2)C3CC3)C(=C1)CC4=CN=C(N=C4N)N)OC
  • InChI=1S/C19H22N4O3/c1-24-15-8-11(7-12-9-22-19(21)23-18(12)20)13-5-6-14(10-3-4-10)26-16(13)17(15)25-2/h5-6,8-10,14H,3-4,7H2,1-2H3,(H4,20,21,22,23) ☒N
  • Key:HWJPWWYTGBZDEG-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Iclaprim is an antibiotic drug candidate that is active against Gram positive organisms.[1][2] It is administered intravenously.[3]: 3 

In vitro, iclaprim is active against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococcus aureus (VRSA), strains of Streptococcus pneumoniae resistant to several common antibiotics, and some Gram-negative bacteria.[4] It is of the diaminopyrimidine dihydrofolate reductase (DHFR)-inhibiting type.

  1. ^ Barton E, MacGowan A (December 2009). "Future treatment options for Gram-positive infections--looking ahead". Clinical Microbiology and Infection. 15 (Suppl 6): 17–25. doi:10.1111/j.1469-0691.2009.03055.x. PMID 19917023.
  2. ^ Abbas M, Paul M, Huttner A (October 2017). "New and improved? A review of novel antibiotics for Gram-positive bacteria". Clinical Microbiology and Infection. 23 (10): 697–703. doi:10.1016/j.cmi.2017.06.010. PMID 28642145.
  3. ^ "Iclaprim for the Treatment of Complicated Skin and Skin Structure Infections" (PDF). FDA. November 20, 2008.
  4. ^ Kohlhoff SA, Sharma R (September 2007). "Iclaprim". Expert Opinion on Investigational Drugs. 16 (9): 1441–1448. doi:10.1517/13543784.16.9.1441. PMID 17714029. S2CID 219289697.